Health
To 340B or not to 340B: A Volatile Time in the 340B Program Presents Challenges (and Opportunities) for Stakeholders
The year 2020 was tumultuous for virtually everyone and everything, and the 340B Program was no exception. At the forefront of 340B Program activity, many drug manufacturers have decided that the Health Resources and Services Administration’s Office